Newsroom
Newsroom
Industry News
Antheia has raised $56 million in a Series C financing round to accelerate its synthetic biology platform, which harnesses engineered yeast to produce essential pharmaceutical...
Industry News
Menlo Park-based Narcan ingredient maker Antheia raised $56 million in Series C funding....
Industry News
Antheia, a Menlo Park, CA-based pharmaceutical ingredient manufacturer, raised $56M in Series C funding....
Industry News
Antheia, manufacturer of a major Narcan ingredient, raised a $56 million Series C round, co-founder and CEO, Christina Smolke, tells Axios....
Press Releases
New funding will support the company’s rapid growth trajectory and efforts to transform pharmaceutical supply chains with its advanced biomanufacturing platform....
Blog Posts
After a busy year marked by major commercial milestones for Antheia, we are excited to announce $56 million in Series C financing. With the support...